# ACUTE CORONARY SYNDROMES

![](https://i.imgur.com/fJcc0x1.jpg)

### Ddx (causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)

• **Nonatherosclerotic coronary artery disease** (_JACC_ 2018;72:2231)

Spasm: Prinzmetal’s variant, cocaine-induced (6% of chest pain + cocaine use r/i for MI)

Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde extension (usually involving RCA → IMI) or mechanical (PCI, surgery, trauma)

Embolism (_Circ_ 2015;132:241): AF, thrombus/myxoma, endocard., prosth valve thrombosis

Vasculitis: Kawasaki syndrome, Takayasu arteritis, PAN, Churg-Strauss, SLE, RA

Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)

• **Ischemia without plaque rupture** (“type 2” MI): ↑ demand (eg, ↑ HR), ↓ supply (eg, HoTN)

• **Direct myocardial injury:** myocarditis; Takotsubo/stress CMP; toxic CMP; cardiac contusion

### 臨床表現 (_JAMA_ 2015;314:1955)

• **Typical angina:** retrosternal pressure/pain/tightness ± radiation to neck, jaw, arms; precip. by exertion, relieved by rest/ NTG. In ACS: new-onset, crescendo or at rest.

• **Associated symptoms:** dyspnea, diaphoresis, N/V, palpitations or light-headedness

• Many MIs (~20% in older series) are initially unrecognized b/c silent or atypical 症狀

• Atypical 症狀s (incl N/V & epig pain) ? more common in ♀, elderly, diabetes, inferior ischemia

### Physical exam

• Signs of ischemia: S4, new MR murmur 2° pap. muscle dysfxn, paradoxical S2, diaphoresis

• Signs of heart failure: ↑ JVP, crackles in lung fields, ⊕ S3, HoTN, cool extremities

• Signs of other vascular disease: asymmetric BP, carotid or femoral bruits, ↓ distal pulses

### Diagnostic studies (_NEJM_ 2017;376:2053)

• **ECG:** ST ↓/↑, TWI, new LBBB, hyperacute Tw; Qw/PRWP may suggest prior MI & ∴ CAD

✔ ECG within 10 min of presentation, with any ∆ in 症狀 & at 6–12 h; compare with baseline

STEMI dx with old LBBB: ≥1 mm STE _concordant_ with QRS (Se 73%, Sp 92%), STD ≥1 mm V1–V3 (Se 25%, Sp 96%), STE ≥5 mm _discordant_ with QRS (Se 31%, Sp 92%)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><a id="page_1-7"></a><p><b>Localization of MI</b></p></td></tr><tr><td><p><b>Anatomic Area</b></p></td><td><p><b>ECG Leads with STE</b></p></td><td><p><b>Coronary Artery</b></p></td></tr><tr><td><p>Septal</p></td><td><p>V<sub>1</sub>–V<sub>2</sub> ± aVR</p></td><td><p>Proximal LAD</p></td></tr><tr><td><p>Anterior</p></td><td><p>V<sub>3</sub>–V<sub>4</sub></p></td><td><p>LAD</p></td></tr><tr><td><p>Apical</p></td><td><p>V<sub>5</sub>–V<sub>6</sub></p></td><td><p>Distal LAD, LCx, or RCA</p></td></tr><tr><td><p>Lateral</p></td><td><p>I, aVL</p></td><td><p>LCx</p></td></tr><tr><td><p>Inferior</p></td><td><p>II, III, aVF ± aVR</p></td><td><p>RCA (~85%), LCx (~15%)</p></td></tr><tr><td><p>RV</p></td><td><p>V<sub>1</sub>–V<sub>2</sub> &amp; V<sub>4</sub>R (most Se)</p></td><td><p>Proximal RCA</p></td></tr><tr><td><p>Posterior</p></td><td><p>ST <i>depression</i> V<sub>1</sub>–V<sub>3</sub> (= STE V<sub>7</sub>–V<sub>9</sub> posterior leads, ✔ if 臨床suspicion)</p></td><td><p>RCA or LCx</p></td></tr></tbody></table>

If ECG non-dx & suspicion high, ✔ leads V7–V9 to assess distal LCX/RCA territory. ✔ R-sided precordial leads in IMI to help detect RV involvement (STE in V4R most Se). STE in III > STE in II and lack of STE in I or aVL suggest RCA rather than LCX culprit in IMI. STE in aVR suggests LM or prox LAD occlusion or diffuse ischemia.

• **Cardiac biomarkers:** ✔ Tn (pref. over CK-MB) at presentation & 3–6 h (? 1hr if hsTn); repeat if 臨床or ECG ∆s; >99th %ile with rise and/or fall in appropriate 臨床setting dx of AMI (see “Chest Pain”); in CKD, ↑ Tn still portends poor prognosis (_NEJM_ 2002;346:2047)

• If low prob, **stress test, CT angio** to 排除 CAD; new wall motion 異常 on TTE suggests ACS

• **Coronary angio** gold standard for epicardial CAD

### Prinzmetal’s (variant) angina

• Coronary spasm → transient STE usually without MI (_but_ MI, AVB, VT can occur)

• 病人 usually young, smokers, ± other vasospastic disorders (eg, migraines, Raynaud’s)

• Angiography: nonobstructive CAD (spasm can be provoked during cath but rarely done)

• 治療: high-dose CCB & standing nitrates (+SL prn), ? α-blockers/statins; d/c smoking; avoid high-dose ASA (can inhibit prostacyclin and worsen spasm), nonselect βB, triptans

• Cocaine-induced vasospasm: CCB, nitrates, ASA; ? avoid βB, but labetalol appears safe

![](https://i.imgur.com/3k11cSC.jpg)

### Approach to triage

• If hx, initial ECG & Tn non-dx, repeat ECG q15–30min × 1 h & Tn 3–6 h (? 1hr if hs) later

• If remain 正常 and low likelihood of ACS, search for alternative causes of chest pain

• If remain 正常, have ruled out MI, _but_ if high suspicion for ACS based on hx, then still need to 排除 UA with stress test to assess for inducible ischemia (or CTA to 排除 epicardial CAD);

if low risk (eg, age ≤70; ∅ prior CAD, CVD, PAD; ∅ rest angina) can do before d/c from ED or as outPt within 72 h (0% mortality, <0.5% MI; _Ann Emerg Med_ 2006;47:427)

if not low risk, admit and initiate Rx for possible ACS and consider stress test or cath

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Acute Anti-Ischemic and Analgesic 治療</b></p></td></tr><tr><td><p><b>Nitrates</b> (SL or IV) 0.3–0.4 mg SL q5min × 3, then consider IV if still 症狀</p></td><td><p>Use for relief of 症狀, Rx for HTN or HF. No clear ↓ in mortality.</p><p><i>Caution</i> if preload-sensitive (eg, HoTN, AS, 症狀 RV infarct); contraindicated if recent PDE5 inhibitor use.</p></td></tr><tr><td><p>β<b>-blockers</b></p><p>eg, metop 25–50 mg PO q6h titrate slowly to HR 50–60 IV only if HTN and no HF</p></td><td><p>↓ ischemia &amp; progression of UA to MI (<span><i>JAMA</i> 1988;260:2259</span>)</p><p>STEMI: ↓ arrhythmic death &amp; reMI, but ↑ cardiogenic shock early (espec if signs of HF) (<span><i>Lancet</i> 2005;366:1622</span>).</p><p><i>Contraindic.</i> PR &gt;0.24 sec, HR &lt;60, 2°/3° AVB, severe bron-chospasm, signs and symptoms HF or low output, risk factors for shock (eg, &gt;70 y, HR &gt;110, SBP &lt;120, late presentation STEMI)</p></td></tr><tr><td><p><b>CCB</b> (nondihydropyridines)</p></td><td><p>If cannot tolerate βB b/c bronchospasm</p></td></tr><tr><td><p><b>Morphine</b></p></td><td><p>Relieves pain/anxiety; venodilation ↓ preload. Do not mask refractory 症狀. May delay antiplt effects of P2Y<sub>1</sub><sub>2</sub> inhib.</p></td></tr><tr><td><p><b>Oxygen</b></p></td><td><p>Use prn for resp distress or to keep S<sub>a</sub>O<sub>2</sub> &gt;90%; no mortality benefit if S<sub>a</sub>O<sub>2</sub> ≥90% (<span><i>NEJM</i> 2017;377:1240</span>)</p></td></tr></tbody></table>

### Other early adjunctive therapy

• **High-intensity statin therapy** (eg, atorva 80 mg qd; PROVE-IT TIMI 22, _NEJM_ 2004;350:1495); ↓ ischemic events with benefit emerging within wks (_JAMA_ 2001;285:1711 & _JACC_ 2005;46:1405); ↓ peri-PCI MI (_JACC_ 2010;56:1099); ? ↓ contrast-induced nephropathy (_NEJM_ 2019;380:2156)

• **Ezetimibe:** ↓ CV events when added to statin (IMPROVE-IT, _NEJM_ 2015;372:1500)

• **ACEI/ARB:** start once hemodynamics and renal function stable

Strong indication for ACEI if heart failure, EF <40%, HTN, DM, CKD; ~10% ↓ mortality, greatest benefit in ant. STEMI or prior MI (_Lancet_ 1994;343:1115 & 1995;345:669)

ARB appear ≈ ACEI (_NEJM_ 2003;349:20); give if contraindic to ACEI

• IABP: can be used for refractory angina when PCI not available

### NSTE-ACS (_CIRC_ 2014;130:e344)

_Key issues are antithrombotic regimen and invasive vs. conservative strategy_

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Antiplatelet Therapy</b></p></td></tr><tr><td><p><b>Aspirin</b></p><p>162–325 mg × 1, then 81 mg qd</p><p>(non–enteric-coated, chewable)</p></td><td><p>50–70% ↓ D/MI (<span><i>NEJM</i> 1988;319:1105</span>)</p><p>Low dose (~81 mg) pref long term (<span><i>NEJM</i> 2010;363:930</span>)</p><p>If allergy, use clopi and/or desensitize to ASA</p></td></tr><tr><td colspan="2"><p><b>P2Y<sub>1</sub><sub>2</sub> (ADP receptor) inhibitor</b> (choose one of the following in addition to ASA).</p><p>Timing (on presentation or at angiography) remains controversial. Some data for upstream clopidogrel (<span><i>JAMA</i> 2012;308:2507</span>). See below for specific recommendations.</p></td></tr><tr><td><p><span>•</span> <b>Ticagrelor</b> (preferred over clopi)</p><p>180 mg × 1 → 90 mg bid</p><p>Reversible, but wait 3–5 d prior to surg. Antidote being developed (<span><i>NEJM</i> 2019;380:1825</span>).</p><p>Use only with ASA &lt;100 mg qd</p></td><td><p>More rapid and potent plt inhib c/w clopi</p><p>16% ↓ CVD/MI/stroke &amp; 21% ↓ CV death c/w clopi; ↑ non-CABG bleeding (<span><i>NEJM</i> 2009;361;1045</span>)</p><p>Given upstream or at time of PCI</p><p>Dyspnea (but S<sub>a</sub>O<sub>2</sub> &amp; 肺功能 正常) &amp; ventricular pauses</p></td></tr><tr><td><p><a id="page_1-8"></a><span>•</span> <b>Prasugrel</b> (preferred over clopi)</p><p>60 mg × 1 if undergoing PCI → 10 mg qd (consider 5 mg/d if &lt;60 kg)</p><p>Wait 7 d prior to surgery</p></td><td><p>More rapid and potent plt inhib c/w clopi</p><p>19% ↓ CVD/MI/stroke in ACS with planned PCI vs. clopi, but ↑ bleeding (<span><i>NEJM</i> 2007;359:2001</span>), incl fatal bleeds</p><p>In NSTE-ACS, should be given at time of PCI and not upstream due to ↑ bleeding (<span><i>NEJM</i> 2013;369:999</span>)</p><p>Contraindic. if h/o TIA/CVA; ? avoid if &gt;75 y</p></td></tr><tr><td><p><span>•</span> <b>Clopidogrel</b><a id="st1"></a><a href="text/part0006_split_004.html#sst1">*</a></p><p>300–600 mg × 1 → 75 mg qd</p><p>Requires ~6 h to steady state</p></td><td><p>ASA+clopi → 20% ↓ CVD/MI/stroke vs. ASA alone ↑ benefit if given hrs <i>prior</i> to PCI (<span><i>JAMA</i> 2012;308:2507</span>), but if require CABG, need to wait &gt;5 d after d/c clopi</p></td></tr><tr><td><p><span>•</span> <b>Cangrelor</b></p><p>Only IV P2Y<sub>1</sub><sub>2</sub> inhibitor</p><p>Rapid onset/offset; t¹⁄² 3–5 min</p></td><td><p>22% ↓ CV events (mostly peri-PCI MI and stent thrombosis) vs. clopi 300 mg at time of PCI; no significant ↑ bleeding (<span><i>NEJM</i> 2013;368:1303</span>)</p><p>Consider for rapidly reversible P2Y<sub>1</sub><sub>2</sub> inhibition during PCI or as bridge to surgery in high-risk 病人 who need to stop P2Y<sub>1</sub><sub>2</sub></p></td></tr><tr><td><p><b>GP IIb/IIIa inhibitors (GPI)</b></p><p>abciximab; eptifibatide; tirofiban</p><p>Infusions given ≤24 h peri &amp; post PCI; shorter (~2 h) as effective with ↓ bleeding (<span><i>JACC</i> 2009;53:837</span>)</p></td><td><p>No clear benefit for routinely starting prior to PCI and ↑ bleeding (<span><i>NEJM</i> 2009;360:2176</span>)</p><p>Consider if refractory ischemia despite optimal Rx while awaiting angio or in high-risk 病人 (eg, large clot burden) at time of PCI, espec if using clopi and no preRx.</p></td></tr></tbody></table>

[\*](text/part0006_split_004.html#st1)~30% pop has ↓ fxn _CYP2C_1_9_ → ↑ CV events if PCI on clopi (_NEJM_ 2009;360:354)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Anticoagulant Therapy (choose one)</b></p></td></tr><tr><td><p><b>UFH:</b> 60 U/kg IVB (max 4000 U) then 12 U/kg/h (max 1000 U/h initially) × 48 h or until end of PCI</p></td><td><p>24% ↓ D/MI (<span><i>JAMA</i> 1996;276:811</span>)</p><p>Titrate to aPTT 1.5–2× control (~50–70 sec)</p><p>Hold until INR &lt;2 if already on warfarin</p></td></tr><tr><td><p><b>Enoxaparin</b> (low-molec-wt heparin) 1 mg/kg SC bid (± 30 mg IVB) (qd if CrCl &lt;30) × 2–8 d or until PCI</p></td><td><p>~10% ↓ D/MI vs. UFH (<span><i>JAMA</i> 2004;292:45,89</span>). Can perform PCI on enox (<span><i>Circ</i> 2001;103:658</span>), but ↑ bleeding if switch b/w enox and UFH.</p></td></tr><tr><td><p><b>Bivalirudin</b> (direct thrombin inhibitor) 0.75 mg/kg IVB at PCI → 1.75 mg/kg/h</p></td><td><p>No diff in bleeding, MI, or death c/w UFH (<span><i>NEJM</i> 2017;377:1132</span>). Use instead of UFH if HIT.</p></td></tr><tr><td><p><b>Fondaparinux</b> (Xa inh) 2.5 mg SC qd</p></td><td><p>Rarely used; must supplement with UFH if PCI.</p></td></tr></tbody></table>

### Coronary angiography (_Circ_ 2014;130:e344)

• **Immediate/urgent coronary angiography** (w/in 2 h) if refractory/recurrent angina or hemodynamic or electrical instability

• **Invasive (INV) strategy** = routine angiography within 72 h

_Early (w/in 24 h) if:_ ⊕ Tn, ST ∆, GRACE risk score ([www.outcomes-massmed.org/grace](http://www.outcomes-massmed.org/grace)) >140 (_NEJM_ 2009;360:2165; _Circ_ 2018;138:2741)

_Delayed (ie, within 72 h) acceptable if without above features but with:_ diabetes, EF <40%, GFR <60, post-MI angina, TRS ≥3, GRACE score 109–140, PCI within 6 mo, prior CABG

32% ↓ rehosp for ACS, nonsignif 16% ↓ MI, no ∆ in mortality c/w cons. (_JAMA_ 2008;300:71).

↑ peri-PCI MI counterbalanced by ↓↓ in spont. MI. Mortality benefit seen in some studies, likely only if cons. strategy with low rate of angio.

• **Conservative (CONS) strategy** = selective angio. Med Rx with pre-d/c stress test; angio only if recurrent ischemia or strongly ⊕ ETT. _Indicated for:_ low TIMI Risk Score, Pt or physician pref in absence of high-risk features, or low-risk women (_JAMA_ 2008;300:71).

![](https://i.imgur.com/ayroHzZ.jpg)

### Figure 1-2 Approach to UA/NSTEMI

![](https://i.imgur.com/GkkDXks.jpg)

### STEMI

### Requisite STE (at J point)

• ≥2 contiguous leads with ≥1 mm (except for V2–V3: ≥2 mm in ♂ and ≥1.5 mm in ♀), or

• New or presumed new LBBB with compelling H&P, or

• True posterior MI: ST depression V1–V3 ± tall Rw with STE on posterior leads (V7–V9)

### Reperfusion (“time is muscle”)

• In PCI-capable hospital, goal should be **primary PCI within 90 min** of 1st medical contact

• In non–PCI-capable hospital, consider _transfer_ to PCI-capable hospital (see below), otherwise **fibrinolytic therapy** within 30 min of hospital presentation

• Do not let decision regarding _method_ of reperfusion delay _time_ to reperfusion

### Primary PCI (_JACC_ 2013;61:e78 & 2016;67:1235)

• 定義: immediate PCI upon arrival to hospital or transfer for immediate PCI

• Indic: STE + 症狀 onset within <12 h; ongoing ischemia 12–24 h after 症狀 onset; shock

• Superior to lysis: 27% ↓ death, 65% ↓ reMI, 54% ↓ stroke, 95% ↓ ICH (_Lancet_ 2003;361:13)

• _Transfer_ to center for 1° PCI superior to lysis (_NEJM_ 2003;349:733), see below

• Routine thrombus aspiration: no benefit, ↑ stroke (_Lancet_ 2015;387:127; 2015;372:1389)

• Consider PCI of non-culprit lesions at time of primary PCI or planned staged procedure because appears to ↓ MACE vs. culprit alone (_NEJM_ 2013;369:1115; _JACC_ 2015;65:963); but may harm if cardiogenic shock (_NEJM_ 2018;379:1699)

<table><colgroup><col></colgroup><tbody><tr><td><p><b>Fibrinolysis vs. Hospital Transfer for Primary PCI: Assess Time and Risk</b></p></td></tr><tr><td><p><span>1.</span> <b>Time required for transport to skilled PCI lab:</b> door-to-balloon &lt;120 min &amp; [door- to-balloon]–[door-to-needle] &lt;1 h favors transfer for PCI</p></td></tr><tr><td><p><span>2.</span> high-risk 病人 (eg, shock) fare better with mechanical reperfusion</p></td></tr><tr><td><p><span>3.</span> <b>Time to presentation:</b> efficacy of lytics ↓ with ↑ time from 症狀 onset, espec &gt;3 h</p></td></tr><tr><td><p><span>4.</span> <b>Risk of fibrinolysis:</b> if high risk of ICH or bleeding, PCI safer option</p></td></tr></tbody></table>

Adapted from ACC/AHA 2013 STEMI Guidelines (_Circ_ 2013;127:529)

### Fibrinolysis

• Indic: STE/LBBB + 症狀 <12 h (& >120 min before PCI can be done); benefit if 症狀 >12 h less clear; reasonable if persist. 症狀 & STE, hemodynamic instability or large territory at risk

• Mortality ↓ ~20% in anterior MI or LBBB and ~10% in IMI c/w ∅ reperfusion Rx

• Prehospital lysis (ie, ambulance): further 17% ↓ in mortality (_JAMA_ 2000;283:2686)

• ~1% risk of ICH; high risk incl elderly (~2% if >75 y), ♀, low wt. ∴ PCI more attractive

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Contraindications to Fibrinolysis</b></p></td></tr><tr><td><p><b>Absolute Contraindications</b></p></td><td><p><b>Relative Contraindications</b></p></td></tr><tr><td><p><span>•</span> Any prior ICH</p><p><span>•</span> Intracranial neoplasm, aneurysm, AVM</p><p><span>•</span> Ischemic stroke or closed head trauma within 3 mo; head/spinal surg. within 2 mo</p><p><span>•</span> Active internal bleeding or known bleeding diathesis</p><p><span>•</span> Suspected aortic dissection</p><p><span>•</span> Severe uncontrollable HTN</p><p><span>•</span> For SK, SK Rx within 6 mo</p></td><td><p><span>•</span> H/o severe HTN, SBP &gt;180 or DBP &gt;110 on presentation (? absolute if low-risk MI)</p><p><span>•</span> Ischemic stroke &gt;3 mo prior</p><p><span>•</span> CPR &gt;10 min; trauma/major surg. within 3 wk</p><p><span>•</span> Internal bleed within 2–4 wk; active PUD</p><p><span>•</span> Noncompressible vascular punctures</p><p><span>•</span> Pregnancy</p><p><span>•</span> Current use of anticoagulants</p><p><span>•</span> For SK, prior SK exposure</p></td></tr></tbody></table>

### Nonprimary PCI

• Rescue PCI if shock, unstable, failed reperfusion, or persistent 症狀 (_NEJM_ 2005;353:2758)

• Routine angio ± PCI within 24 h of successful lysis: ↓ D/MI/revasc (_Lancet_ 2004;364:1045) and within 6 h ↓ reMI, recurrent ischemia, & HF compared to within 2 wk (_NEJM_ 2009;360:2705);

∴ _if lysed at non-PCI-capable hosp., consider transfer to PCI-capable hosp. as soon as possible espec if hi-risk (eg, ant. MI, IMI with_ ↓ _EF or RV infarct, extensive STE/LBBB, HF_, ↓ _BP or_ ↑ _HR)_

• _Late_ PCI (median day 8) of occluded infarct-related artery: no benefit (_NEJM_ 2006;355:2395)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Antiplatelet Therapy</b></p></td></tr><tr><td><p><b>Aspirin</b> 162–325 mg × 1</p><p>(crushed/chewed) then 81 mg qd</p></td><td><p>23% ↓ in death (<span><i>Lancet</i> 1988;ii:349</span>)</p><p>Should not be stopped if CABG required</p></td></tr><tr><td><p><b>P2Y<sub>1</sub><sub>2</sub> inhibitor</b></p><p>Give as soon as possible (do not wait for angio) b/c onset inhib delayed in STEMI 病人</p><p>Ticagrelor or prasugrel (if PCI) as detailed above</p><p>Clopidogrel: 600 mg pre-PCI; 300 mg if lysis (no LD if &gt;75 y) → 75 mg qd</p></td><td><p><i>Lysis:</i> clopidogrel 41% ↑ in patency, 7% ↓ mort, no ∆ major bleed or ICH (<span><i>NEJM</i> 2005;352:1179; <i>Lancet</i> 2005;366:1607</span>); no data for pras or ticag with lytic</p><p><i>PCI:</i> prasugrel and ticagrelor ↓ CV events c/w clopi (<span><i>Lancet</i> 2009;373:723 &amp; <i>Circ</i> 2010;122:2131</span>)</p><p>Prehospital ticagrelor may be safe &amp; ? ↓ rate of stent thrombosis (<span><i>NEJM</i> 2014;371:1016</span>)</p></td></tr><tr><td><p><b>GP IIb/IIIa inhibitors</b></p><p>abciximab, eptifibatide, tirofiban</p></td><td><p><i>Lysis:</i> no indication (<span><i>Lancet</i> 2001;357:1905</span>)</p><p><i>Peri-PCI:</i> 60% ↓ D/MI/UR (<span><i>NEJM</i> 2001;344:1895</span>)</p></td></tr></tbody></table>

Adapted from ACC/AHA 2013 STEMI Guidelines Update (_Circ_ 2013;127:529); _Lancet_ 2013;382:633

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Anticoagulant Therapy (choose one)</b></p></td></tr><tr><td><p><b>UFH</b></p><p>60 U/kg IVB (max 4000 U)</p><p>12 U/kg/h (max 1000 U/h initially)</p></td><td><p>No demonstrated mortality benefit</p><p>↑ patency with fibrin-specific lytics</p><p>Titrate to aPTT 1.5–2× control (~50–70 sec)</p></td></tr><tr><td><p><b>Enoxaparin</b></p><p><i>Lysis:</i> 30 mg IVB → 1 mg/kg SC bid (adjust for age &gt;75 &amp; CrCl)</p><p><i>PCI:</i> 0.5 mg/kg IVB</p></td><td><p><i>Lysis:</i> 17% ↓ D/MI with ENOX × 7 d vs. UFH × 2 d (<span><i>NEJM</i> 2006;354:1477</span>)</p><p><i>PCI:</i> ↓ D/MI/revasc and ≈ bleeding vs. UFH (<span><i>Lancet</i> 2011;378:693</span>)</p></td></tr><tr><td><p><b>Bivalirudin</b></p><p>0.75 mg/kg IVB → 1.75 mg/kg/hr IV</p></td><td><p><i>PCI:</i> similar bleeding, ± ↑ MI, ↑ stent thromb (<span><i>Lancet</i> 2014;384:599; <i>NEJM</i> 2017;377:1132</span>)</p></td></tr></tbody></table>

Fondaparinux can be used (if CrCl >30 mL/min) in setting of lysis, where superior to UFH with less bleeding (_JAMA_ 2006;295:1519). Adapted from ACC/AHA 2013 STEMI Guidelines (_Circ_ 2013;127:529; _Lancet_ 2013;382:633)

### LV failure (occurs in ~25%)

• Diurese to achieve PCWP ~14 → ↓ pulmonary edema, ↓ myocardial O2 demand

• ↓ Afterload → ↑ stroke volume & CO, ↓ myocardial O2 demand. Can use IV NTG or nitroprusside (although risk of coronary steal) → short-acting ACEI.

• Inotropes if HF despite diuresis & ↓ afterload; use dopamine, dobutamine, or milrinone

• **Cardiogenic shock** (~7%) = MAP <60 mmHg, CI <2.2 L/min/m2, PCWP >18 mmHg.

If not done already, coronary revasc (_NEJM_ 1999;341:625)

Support with inotropes or mechanical circulatory support to keep CI >2

### Intraaortic balloon pump (IABP) counterpulsation offers ~0.5 L/min CO and ↑ coronary perfusion, but no survival benefit if early revasc (_NEJM_ 2012;367:1287)

### Axial flow pumps (eg, Impella) offer up to 3–5 L/min CO, but no data that improves 臨床outcomes (_JACC_ 2017;69:278)

### IMI complications (_Circ_ 1990;81:401; _NEJM_ 1994;330:1211; _JACC_ 2003;41:1273)

• **Heart block:** ~20%, occurs in part because RCA typically supplies AV node

40% on present., 20% within 24 h, rest by 72 h; high-grade AVB can develop abruptly

Rx: atropine, epi, aminophylline (100 mg/min × 2.5 min), temp pacing wire

• **RV infarct:** proximal RCA occlusion → ↓ flow to RV marginals

Angiographically present in 30–50% of cases, but only ~1/2 clinically significant

HoTN; ↑ JVP, ⊕ Kussmaul’s; ≥1 mm STE in V4R; RA/PCWP ≥0.8; RV dysfxn on TTE

Rx: optimize preload (RA goal 10–14 mmHg; _BHJ_ 1990;63:98); ↑ contractility (dobutamine); maintain AV synchrony (pacing as necessary); reperfusion (_NEJM_ 1998;338:933); mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)

### Mechanical complications (incid. <1% for each; typically occur a few days post-MI)

• **Free wall rupture:** ↑ risk with lysis, large MI, ↑ age, ♀, HTN; 表現為 PEA or hypoTN, pericardial 症狀, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, **surgery**

• **VSD:** large MI in elderly; AMI → apical VSD, IMI → basal septum; 90% with harsh murmur ± thrill (_NEJM_ 2002;347:1426); Rx: diuretics, vasodil., inotropes, IABP, **surgery**, perc. closure

• **Papillary muscle rupture:** more common after IMI (PM pap m. supplied by PDA alone) than AMI (AL supplied by OMs & diags); 50% with new murmur; ↑ _v_ wave in PCWP tracing; asymmetric pulmonary edema on CXR. Rx: diuretics, vasodilators, IABP, **surgery**.

### Arrhythmias post-MI (treat all per ACLS protocols if unstable or symptomatic)

• **AF** (10–16% incidence): βB or amio, ± digoxin (particularly if HF), heparin

• **VT/VF:** lido or amio × 6–24 h, then reassess; ↑ βB as tol., replete K & Mg, 排除 ischemia;

VT <48 h post-MI does _not_ worsen prognosis; >48 h, consider ICD (see below)

• Accelerated idioventricular rhythm (AIVR): slow VT (<100 bpm), often seen after

successful reperfusion; typically  無症狀, self-terminates, and does not require 治療

• **Backup transcutaneous _or_ transvenous pacing** if: 2° AVB type II; BBB + AVB

• **Transvenous pacing** if: 3° AVB; new BBB + 2° AVB type II; alternating LBBB/RBBB

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Other Post-MI Complications</b></p></td></tr><tr><td><p><b>Complication</b></p></td><td><p><b>臨床表現</b></p></td><td><p><b>治療</b></p></td></tr><tr><td><p><b>LV thrombus</b></p></td><td><p>~30% incid. (espec lg antero-apical MI)</p></td><td><p>Anticoagulate × 3–6 mo</p></td></tr><tr><td><p><b>Ventricular aneurysm</b></p></td><td><p>Noncontractile outpouching of LV; 8–15% incid. (espec ant); persist STE</p></td><td><p>Surgery or perc repair if HF, thromboemboli, arrhythmia</p></td></tr><tr><td><p><b>Ventricular pseudoaneurysm</b></p></td><td><p>Rupture (narrow neck) → sealed by thrombus and pericardium (esp in inf).</p></td><td><p>Urgent surgery (or percutaneous repair)</p></td></tr><tr><td><p><b>Pericarditis</b></p></td><td><p>10–20% incid.; 1–4 d post-MI ⊕ pericardial rub; ECG ∆s rare</p></td><td><p>High-dose ASA, colchicine, narcotics; minimize anticoag</p></td></tr><tr><td><p><b>Dressler’s syndrome</b></p></td><td><p>&lt;4% incid.; 2–10 wk post-MI fever, pericarditis, pleuritis</p></td><td><p>High-dose aspirin, NSAIDs</p></td></tr></tbody></table>

### Prognosis

• In registries, in-hospital mortality is 6% with reperfusion Rx (lytic or PCI) and ~20% without

• TIMI Risk Score for STEMI (includes age, time to Rx, anterior MI or LBBB, Killip class, tachycardia, HoTN) defines 30-d mortality after STEMI (_JAMA_ 2001;286:1356)

CHECKLIST AND LONG\-TERM POST\-ACS MANAGEMENT

### Risk stratification

• Stress test if anatomy undefined; consider stress if signif residual CAD post-PCI of culprit

• Assess LVEF prior to d/c; EF ↑ ~6% in STEMI over 6 mo (_JACC_ 2007;50:149)

### Medications (barring contraindications)

• **Aspirin:** 81 mg daily (no clear benefit to higher doses)

• **P2Y12 inhib** (ticagrelor or prasugrel preferred over clopi): treat for _at least_ 12 mo

Prolonged Rx >12 mo → ↓ MACE & CV death, ↑ in bleeding, but no ↑ ICH. Beyond 1st 12 mo, ticag 60 bid preferred to 90, b/c better tolerability (_NEJM_ 2015;372:1791; _EHJ_ 2016;37:390).

PPIs ↓ GI complic; some PPIs ↓ antiplt effect, but no clear ↑ in CV risk (_NEJM_ 2010;363:1909)

• **β-blocker:** 23% ↓ mortality after MI

• **LDL-C** management: benefit with lowering LDL-C to <<40 mg/dl (_Lancet_ 2017;390:1962)

_Statin_: high-intensity (eg, atorva 80 mg, PROVE-IT TIMI 22, _NEJM_ 2004;350:1495)

_Ezetimibe_: ↓ CV events when added to statin (IMPROVE-IT, _NEJM_ 2015;372:1500)

_PCSK9 inhibitor_: ↓ CV events when added to statin (_NEJM_ 2017;376:1713; 2018;379:2097)

• **ACEI:** lifelong if HF, ↓ EF, HTN, DM; 4–6 wk or at least until hosp. d/c in all STEMI

? long-term benefit in CAD without HF (_NEJM_ 2000;342:145 & 2004;351:2058; _Lancet_ 2003;362:782)

• **Aldosterone antag:** 15% ↓ mort. if EF <40% & either signs and symptoms of HF or DM (_NEJM_ 2003;348:1309)

• Nitrates: standing if symptomatic; SL NTG prn for all

• Ranolazine: ↓ recurrent ischemia, no impact on CVD/MI (_JAMA_ 2007;297:1775)

• Oral anticoag: if needed (eg, AF, LV thrombus), consider DOAC instead of warfarin; some data for reduced-dose DOAC but unclear if ischemic stroke prevention adeq. (_NEJM_ 2016; 375:2423 & 2017;377:1513). Clopi (not ticag or pras). Stopping ASA (? after ~1 wk) ↓ bleed risk by 40–50%, but trend small ↑ MI & stent thromb. (_Lancet_ 2013;381:1107; _NEJM_ 2019;379:1509).

• In 病人 without indic. for anticoag, once DAPT completed, rivaroxaban 2.5 bid + ASA ↓ MACE & CV death and ↑ bleeding vs. ASA monoRx (_NEJM_ 2017;377:1319)

### ICD (_NEJM_ 2008;359:2245; _Circ_ 2014;130:94)

• Sust. VT/VF >2 d post-MI without revers. isch; ? ↓ death with _wearable_ defib (_NEJM_ 2018;379:1205)

• 1° prevention of SCD if post-MI EF ≤30–40% (NYHA II–III) or ≤30–35% (NYHA I); wait 40 d after MI (_NEJM_ 2004;351:2481 & 2009;361:1427)

### Risk factors and lifestyle modifications (_Circ_ 2014;129(Suppl 2):S1 & S76)

• Low chol. (<200 mg/d) & fat (<7% saturated) diet; ? Ω-3 FA.

• LDL-C at least <70 mg/dl (& ≥50% ↓ in LDL-C) (_Circ_ 2019;139:e1082)

• BP <130/80 (_JACC_ 2018;71:e127); quit smoking

• If diabetic, tailor HbA1c goal based on Pt (avoid TZDs and saxa if HF); GLP1-RA & SGLT2i ↓ MACE & SGLT2i ↓ hospitalization for HF (_Lancet_ 2019;393:31 & _Circ_ 2019;139:2022)

• Exercise (30–60′ 5–7×/wk) 1–2 wk after revasc; cardiac rehab; BMI goal 18.5–24.9 kg/m2

• Influenza & _S. pneumo_ vaccines (_JAMA_ 2013;310:1711; _NEJM_ 2018;378:345); ✔ for depression
